Bringing the fundamentals into focus…
Back to C4 Therapeutics, Inc.
How C4 Therapeutics, Inc. stacks up
CCCC · against 410 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #259 of 411 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score153 peers with a valuation score of 0–9, including CCCC · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -50.2% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -25.7% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -21.6% vs peer median 0.0%
Metric by metric
Position: dot = CCCC, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CCCC | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 397 reported | -28.7% | 0.0% | 11% | 30% | |
| EBITDA yieldHigher is better · 416 reported | -50.2% | 3.0% | 7% | 50% | |
| Free cash flow yieldHigher is better · 196 reported | -21.6% | -8.4% | 23% | 20% | |
| Book yieldHigher is better · 408 reported | 62.7% | 50.4% | 62% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around CCCC| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 259 | 241M USD | 8 | ||
| 259 | 675M USD | 8 | ||
| 259 | 479M USD | 8 | 34 | |
| 259 | 393M USD | 8 | 50 | |
| 259 | 395M USD | 8 | 30 | |
| 259 | 296M USD | 8 | 26 | |
| 259 | 560M USD | 8 | 42 | |
| 259 | 775M USD | 8 | 31 | |
| 259 | 475M USD | 8 | 22 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score